Alphabet-A
GOOGL
Alphabet-C
GOOG
MicroStrategy
MSTR
Tesla
TSLA
Ecopetrol
EC
US Stock MarketDetailed Quotes
RHHBY ROCHE HOLDING AG
- 35.640
- -0.830-2.28%
15min DelayClose Dec 10 16:00 ET
227.18BMarket Cap19.01P/E (TTM)
36.370High35.610Low1.23MVolume36.350Open36.470Pre Close44.10MTurnover0.02%Turnover Ratio17.59P/E (Static)6.37BShares42.43052wk High6.90P/B227.18BFloat Cap29.20052wk Low1.36Dividend TTM6.37BShs Float49.895Historical High3.80%Div YieldTTM2.08%Amplitude-3.794Historical Low35.877Avg Price1Lot Size
ROCHE HOLDING AG News
Reported Earlier, Roche's Genentech Presents Long-Term Data at ASH 2024 Highlighting Durable Remissions With Fixed-Duration Columvi And Lunsumio
Biogen Downgraded to Hold by Jefferies, Ocrevus Royalties Cited
Reported Sunday, Roche's Genentech Showcases Polivy's Transformative Impact On Frontline DLBCL Treatment: Five-Year POLARIX Trial Results Presented At ASH 2024
Kepler Capital Sticks to Their Buy Rating for Roche Holding AG (RHHVF)
FDA Accepts Roche's Columvi SBLA for Expanded Use in Lymphoma
Roche (RHHBY.US) CD20/CD3 bispecific antibody new indication application accepted by the FDA.
Roche (RHHBY.US) announced that the FDA has accepted the supplemental biological product license application (sBLA) for glofitamab.
FDA Accepts Genentech's SBLA For Columvi Combination Therapy For Relapsed Or Refractory Diffuse Large B-Cell Lymphoma
Roche (RHHBY.US) reached a nearly 0.9 billion dollar collaboration to develop therapies for autoimmune diseases.
COUR Pharmaceuticals announced a strategic collaboration and licensing agreement with Genentech, a subsidiary of Roche (RHHBY.US).
Roche Holding AG (RHHVF) Gets a Sell From J.P. Morgan
Sanofi will invest approximately 1 billion euros to build a new insulin production base in peking.
Sanofi will invest approximately 1 billion euros (about 1.1 billion US dollars) to build a new insulin production facility in Peking, marking its largest single investment in china to date and part of its broader global strategy to expand production capacity in asia. The French pharmaceutical company stated on WeChat that this will be Sanofi's fourth production facility in china and its second in Peking, focusing on meeting the medication needs of local diabetes patients. Sanofi is one of the largest insulin producers globally, and the potential in the diabetes treatment market in china is immense. Sanofi noted that as of 2021, around 0.14 billion adults in mainland china suffer from diabetes.
Sanofi Unveils $1 Billion China Investment to Boost Production
Intron Health Lifts Price Target on Roche Holding AG
Roche Holding AG Rises Thursday
Roche Signs Digital Pathology MoU in Egypt
Why Is Eye Disease-Focused Outlook Therapeutics Stock Trading Lower On Wednesday?
Barclays Remains a Hold on Roche Holding AG (RHHVF)
Why This Gene-Therapy Company's Stock Is Rising 228% -- Barrons.com
Roche to Acquire CAR-T Cell Therapy Focused Poseida for $1.5B
Roche's Proposed Acquisition Of Poseida Therapeutics Poised To Establish New Core Capability In Cell Therapy For Cancer And Autoimmune Diseases: Details
Roche Holding AG (RHHVF) Receives a Sell From Goldman Sachs
Trending US Stocks
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries
Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.
